Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 10 | 2022 | 42 | 1.650 |
Why?
|
| Hemorrhage | 8 | 2021 | 75 | 0.670 |
Why?
|
| Hemophilia B | 4 | 2020 | 10 | 0.510 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 11 | 0.490 |
Why?
|
| Factor VIII | 7 | 2023 | 27 | 0.440 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 37 | 0.370 |
Why?
|
| Heparin | 2 | 2020 | 27 | 0.370 |
Why?
|
| Hemarthrosis | 3 | 2021 | 15 | 0.360 |
Why?
|
| Anticoagulants | 2 | 2020 | 102 | 0.340 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.320 |
Why?
|
| Factor IX | 2 | 2020 | 5 | 0.320 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 31 | 0.310 |
Why?
|
| Autoantibodies | 3 | 2006 | 103 | 0.310 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 258 | 0.290 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 12 | 0.260 |
Why?
|
| Exercise Therapy | 1 | 2006 | 112 | 0.250 |
Why?
|
| Thrombophilia | 2 | 2020 | 7 | 0.250 |
Why?
|
| Hemostasis | 2 | 2016 | 11 | 0.240 |
Why?
|
| Humans | 26 | 2023 | 29851 | 0.240 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 14 | 0.230 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 19 | 0.230 |
Why?
|
| Hemostatics | 1 | 2023 | 12 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 31 | 0.220 |
Why?
|
| Adult | 13 | 2023 | 8748 | 0.220 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.210 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 4 | 0.210 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 14 | 0.200 |
Why?
|
| Young Adult | 7 | 2023 | 1969 | 0.190 |
Why?
|
| Physical Therapists | 1 | 2021 | 3 | 0.190 |
Why?
|
| Adolescent | 7 | 2023 | 2334 | 0.190 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 4 | 0.180 |
Why?
|
| Serum Albumin | 1 | 2020 | 24 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 43 | 0.180 |
Why?
|
| Genetic Variation | 2 | 2017 | 110 | 0.170 |
Why?
|
| Health Literacy | 1 | 2021 | 105 | 0.170 |
Why?
|
| Autoimmune Diseases | 3 | 2006 | 64 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 13 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 20 | 0.160 |
Why?
|
| Factor VIIa | 1 | 2017 | 9 | 0.150 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Blood Coagulation | 1 | 2017 | 21 | 0.150 |
Why?
|
| Joint Diseases | 1 | 2018 | 111 | 0.140 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Albumins | 1 | 2016 | 35 | 0.130 |
Why?
|
| Male | 11 | 2023 | 15871 | 0.130 |
Why?
|
| Child | 4 | 2023 | 1379 | 0.130 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 18 | 0.120 |
Why?
|
| Middle Aged | 8 | 2020 | 9963 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 696 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 857 | 0.110 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.100 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 7 | 0.100 |
Why?
|
| United States | 4 | 2018 | 2346 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 66 | 0.090 |
Why?
|
| Female | 7 | 2023 | 16430 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 129 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 19 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2008 | 19 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2008 | 59 | 0.080 |
Why?
|
| Liver | 1 | 2008 | 175 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 69 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 337 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 58 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 2467 | 0.070 |
Why?
|
| Ankle Joint | 1 | 2006 | 41 | 0.070 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 8 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.070 |
Why?
|
| Microcirculation | 1 | 2005 | 39 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 456 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 80 | 0.070 |
Why?
|
| Syndrome | 1 | 2005 | 88 | 0.070 |
Why?
|
| Fever | 1 | 2005 | 40 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 364 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 68 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 3561 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 3 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 8 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2006 | 131 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 117 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 399 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 677 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 194 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 80 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Paraproteins | 1 | 2004 | 2 | 0.060 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Biopolymers | 1 | 2004 | 6 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.060 |
Why?
|
| Autoantigens | 1 | 2004 | 39 | 0.060 |
Why?
|
| Plasma | 1 | 2023 | 34 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 149 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 504 | 0.060 |
Why?
|
| Pregnancy | 2 | 2020 | 388 | 0.060 |
Why?
|
| Apoptosis | 1 | 2004 | 259 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2023 | 65 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1187 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 707 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 1859 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2001 | 23 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 42 | 0.050 |
Why?
|
| Hip Joint | 1 | 2006 | 357 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 654 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 119 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 1824 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4930 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 5 | 0.050 |
Why?
|
| North America | 1 | 2020 | 39 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 102 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 9621 | 0.050 |
Why?
|
| Shoulder Joint | 1 | 2006 | 577 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 636 | 0.040 |
Why?
|
| Knee Joint | 1 | 2006 | 800 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 403 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 3 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 3 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 3325 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2017 | 3 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2017 | 18 | 0.040 |
Why?
|
| Pedigree | 1 | 2017 | 77 | 0.040 |
Why?
|
| Homozygote | 1 | 2017 | 22 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 80 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 122 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2017 | 69 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 43 | 0.040 |
Why?
|
| Transfection | 1 | 2017 | 130 | 0.040 |
Why?
|
| Protein Binding | 1 | 2017 | 125 | 0.040 |
Why?
|
| Collagen | 1 | 2017 | 102 | 0.040 |
Why?
|
| Heterozygote | 1 | 2017 | 103 | 0.040 |
Why?
|
| Anxiety | 1 | 2018 | 157 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 28 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 5 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 12 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 78 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 74 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 643 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 446 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 970 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 384 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 472 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1126 | 0.030 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 7 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 7 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 20 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 17 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 25 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 42 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 112 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 202 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 224 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 309 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 332 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 334 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 435 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1628 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 56 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 16 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 48 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 74 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 68 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2006 | 34 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 957 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 56 | 0.020 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 8 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 29 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 25 | 0.020 |
Why?
|
| Placenta | 1 | 2004 | 13 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 135 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 379 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 364 | 0.020 |
Why?
|
| Gestational Age | 1 | 2004 | 75 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 132 | 0.020 |
Why?
|
| Reference Values | 1 | 2004 | 231 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 329 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 682 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 558 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 201 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 350 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 4639 | 0.010 |
Why?
|